At a glance

ClinicalIndex Comparison Record

Phase 1Completed

Drug / intervention

LMB-2 immunotoxinbiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002765

NCT00002765Phase 1Completed

Compare CT.gov

PHASE I STUDY OF ANTI-TAC(Fv)-PE38 (LMB-2), A RECOMBINANT SINGLE-CHAIN IMMUNOTOXIN FOR TREATMENT OF TAC-EXPRESSING MALIGNANCIES

National Cancer Institute (NCI)·interventional·Posted May 6, 2003·Updated Apr 29, 2015

In Brief

A Phase 1 clinical trial evaluating LMB-2 immunotoxin for Leukemia and Lymphoma. Completed, across 2 sites.

Detailed Summary

RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of LMB-2 immunotoxin in treating patients who have leukemia or lymphoma.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLeukemia, Lymphoma

CountriesUnited States

Collaborators--

Timeline

Phase 1CompletedFinished

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartApr 1996

First PostedMay 2003

TodayJul 2026

First PostedMay 6, 2003

Enrollment StartApr 1, 1996

TodayJul 2, 2026

Posted 23.2 years ago

Interventions

LMB-2 immunotoxinbiological